Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Other Non-Current Liabilities: 2020-2023

Historic Other Non-Current Liabilities for ADC Therapeutics (ADCT) over the last 2 years, with Sep 2023 value amounting to $305.3 million.

  • ADC Therapeutics' Other Non-Current Liabilities rose 46.61% to $305.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $305.3 million, marking a year-over-year increase of 46.61%. This contributed to the annual value of $838,000 for FY2022, which is 99.62% down from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Other Non-Current Liabilities is $305.3 million, which was up 2.00% from $299.3 million recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Other Non-Current Liabilities ranged from a high of $305.3 million in Q3 2023 and a low of $208 during Q3 2020.
  • Its 3-year average for Other Non-Current Liabilities is $208.0 million, with a median of $214.6 million in 2021.
  • In the last 5 years, ADC Therapeutics' Other Non-Current Liabilities spiked by 103,186,919.23% in 2021 and then crashed by 99.62% in 2022.
  • ADC Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $208 in 2020, then spiked by 103,186,919.23% to $218.7 million in 2021, then slumped by 99.62% to $838,000 in 2022, then spiked by 46.61% to $305.3 million in 2023.
  • Its Other Non-Current Liabilities stands at $305.3 million for Q3 2023, versus $299.3 million for Q2 2023 and $216.6 million for Q1 2023.